Back to News
Nov 5, 2025 12:00 PM

Teva Pharma's Key Branded Drugs Fuel Strong Revenue Growth, Lifts Full-Year Profit Outlook

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) reported its third-quarter 2025 financial results on Wednesday, with total revenue of $4.48 billion, beating analysts' expectations of $4.35 billion, according to Benzinga Pro.

Revenues increased 3% year-over-year in U.S. dollars or 1% in local currency.

Key brands continue to drive growth, with revenues up 33% in local currency to $830 million.

Austedo (Huntington’s disease drug) sales increased 38% to $618 million. Increasing Austedo 2025 revenue outlook to $2.05 billion – $2.15 billion.

Ajovy (migraine drug) sales reached $168 million (+19% LC YoY). Reaffirming the ...